Mark T. Fleming, M.D.
@MarkTFlemingMD1
Followers
193
Following
250
Media
7
Statuses
172
Manojkumar Bupathi, MD, MS, highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and more. #oncology #pcsm
onclive.com
Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal...
1
2
3
3rd year oncology fellows: We're hiring for our Eugene practice. Join a top 10% MGMA practice with incredible clinical research and sub-specialization opportunities. 4d clinic schedule with pretty light hospital responsibilities. Group includes rad onc / Gyn onc and 25 docs!
8
13
53
The MSK Genitourinary Oncology Service is seeking a GU medical oncologist focused on prostate cancer clinical and translational research at the assistant professor level. Join a great team! @morr316 @TheWonkologist @alaccetti @DRathkopf @MSK_DeptOfMed
https://t.co/ndSDIZkLRo
2
6
24
Standing next to the GU Allstars at #ASCO23 with @DrTHut @mkbupathi . They did a wonderful job!So proud of them! The Science of Collaboration Begins With Us @SarahCannonDocs @BurrisSkip @DavidRSpigel
3
4
18
Dr. Danso moderated this afternoon’s #ASCO23 metastatic breast cancer session where @ErikaHamilton9 delivered exciting data on a phase 2 HER3-Dxd study @DaiichiSankyo #VirginiaOncologyAssociates
0
8
17
Phase 3 #THOR study: Results of erdafitinib vs chemotherapy in patients with advanced or #mUC with select fibroblast growth factor receptor alterations. Presentation by @y_loriot @GustaveRoussy. #ASCO23 written coverage by @zklaassen_md > https://t.co/GkBXFlleyU
@ASCO
0
9
17
FGFR important in UC. Should be tested in all. Great presentation - as always by Dr Siefer-Radtke.
Dr. Siefer-Radtke presented the updated results of the Ph2 NORSE study evaluating Erdafitinib-Cetrelimab Vs. Erdafitinib alone in FGFR-alt mUC cis-ineligible pts in the 1st line. The addition of Cetrelimab appeared (Ph2 preliminary data) to improve ORR, CR, PFS and OS. #ASCO23
0
1
2
Powerhouse brainy @BraunMDPhD @YaleCancer w/ such excellent graphics & insightful discussion on 1st line & refractory #kidneycancer. Decision tree is spot on!! And patient perspectives @kccure are important for shared decision making. Thanks for plug on #PDIGREE! @asco #ASCO23
1
22
55
@BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23
2
11
18
Proud and excited to have @IshwariaMD @VivekSubbiah join our @SarahCannonDocs team ! Already making an impact @ASCO
0
8
74
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
2
98
247
Impressive presentation by @DrTHut regarding updated CLEAR data Len + Pembro - it works. Kidney/Bladder Session chaired by @mkbupathi. @SarahCannonDocs showing the science collaboration begins with us! The GU committee allstars are very proud:@BGarmezy @MikeLattanzi @jeffyoriomd.
0
3
9
Spent a good evening thinking about #prostatecancer w @MarkTFlemingMD1 @sartor_oliver @morr316 @bilenma @koshkin85 #AnaAparicio @twardowski_aw #RobDreicer @bengartrell #DanGeynisman— haven’t seen some of these colleagues since before COVID!! @ASCO #ASCO23
0
2
6
I’m proud to have the opportunity to work with this outstanding person and amazing doctor. Congratulations @WilliamOhMD !
Congratulations to our Chief Medical Officer, @WilliamOhMD, on being named a 2023 AAPI (Asian American Pacific Islander) Top Doctor. Thank you for all you do to support the Foundation and #prostatecancer research https://t.co/J02YQsUn0i
1
1
10
Ab#5015 #ASCO23 @ASCO : In PANTHER Ph 2 trial: Rx with apalutamide + abiraterone showed promising efficacy in NHT naive Black pts in 1st line mCRPC #prostatecancer➡️rPFS, OS, PSA 50% response👇 Congrats @Daniel_J_George and team for these clinically relevant data @AarmstrongDuke
0
14
23
For 30 years, we’ve expanded access to cutting-edge therapies and have conducted 700+ first-in-human trials. We could not have done this without our expert physicians, talented clinical teams, and everyone behind the scenes who live our mission to serve patients every day.
0
5
24
1 week to help @WIMSummit, @ShikhaJainMD, @GoHealio by voting for Woman Disruptor of the Year: https://t.co/Go8fI6UQE2
@NCIDirector, @theNCI
@BarbaraMcAneny
@AnnPartridgeMD
@rachnatshroff
@dapattmd Karen Kim, @UChicagoCancerCenter
#HealioInnovators
0
1
5
Fighting Prostate Cancer With Exercise (Part 2): What Kind of Exercise? | Prostate Cancer Foundation
pcf.org
There’s a wide variety of ways you can get the cardiorespiratory benefit that also may help slow down prostate cancer. I Have Prostate Cancer. What Kind of Exercise is Good for Me? The short answer...
0
11
26
NATALEE trial meets primary endpoint at interim analysis! Adjuvant Ribociclib (400mg) + AI improved iDFS compared to AI alone in patients with stage II, III ER+ breast cancer regardless of LN improvement. @Novartis #breastcancer
novartis.com
0
2
2
Payer delays risk access to timely care for people w cancer. ASCO member @dapattmd shares a powerful example of how #priorauthorization impedes care. It’s why we’re urgently asking lawmakers to #FixPriorAuth & protect pts w cancer. https://t.co/DFMlmELaIY
#ASCOAdvocacy
ama-assn.org
Peer-to-peer (P2P) consults are often required to overcome prior-authorization hurdles. But with metastatic cancer, care delayed is care denied.
0
8
19